1.Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346, 1221–1231.
2.Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123, 1705–1725.
3.Clark JM, Brancati FL & Diehl AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122, 1649–1657.
4.Kleiner DE, Brunt EM, Van Natta M et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321.
5.Levene AP, Kudo H, Thursz MR et al. (2010) Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver? Hepatology 51, 1859–1860.
6.Gilmore IT, Burroughs A, Murray-Lyon IM et al. (1995) Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 36, 437–441.
7.Schwenzer NF, Springer F, Schraml C et al. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51, 433–445.
8.Mehta SR, Thomas EL, Bell JD et al. (2009) Non-invasive means of measuring hepatic fat content. World J Gastroenterol 14, 3476–3483.
9.O'Regan DP, Callaghan MF, Wylezinska-Arridge M et al. (2008) Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3·0T-feasibility. Radiology 247, 550–557.
10.Thomas EL, Hamilton G, Patel N et al. (2005) Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54, 122–127.
11.Cobbold JF, Patel JH, Goldin RD et al. (2010) Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. J Hepatol 52(1), 16–24.
12.Browning JD, Szczepaniak LS, Dobbins R et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395.
13.Szczepaniak LS, Nurenberg P, Leonard D et al. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288, E462–E468.
14.Guiu B, Petit JM, Loffroy R et al. (2009) Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 250, 95–102.
15.Bedogni G, Bellentani S, Miglioli L et al. (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6, 33.
16.Church TS, Kuk JL, Ross R et al. (2006) Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130, 2023–2030.
17.Angulo P, Hui JM, Marchesini G et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846–854.
18.Guha IN, Parkes J, Roderick PR et al. (2006) Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55, 1650–1660.
19.Alberti KG, Zimmet P & Shaw J (2006) Metabolic syndrome – a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 469–480.
20.Ratziu V, Bellentani S, Cortez-Pinto H et al. (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (Epublication ahead of print version).
21.Day CP & James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845.
22.Fabbrini E, Sullivan S & Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679–689.
23.Cheung O & Sanyal AJ (2009) Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 25, 230–237.
24.Anstee QM & Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87, 1–16.
25.Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16, 663–678.
26.Reddy JK (2001) Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 281, G1333–G1339.
27.Yamaguchi K, Yang L, McCall S et al. (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366–1374.
28.Cusi K (2009) Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 13, 545–563.
29.Leclercq IA, Farrell GC, Field J et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105, 1067–1075.
30.Bruce KD, Cagampang FR, Argenton M et al. (2009) Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 50, 1796–1808.
31.Cobbold JF, Anstee QM, Goldin RD et al. (2009) Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin Sci (Lond) 116, 403–413.
32.Allard JP, Aghdassi E, Mohammed S et al. (2008) Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 48, 300–307.
33.Puri P, Wiest MM, Cheung O et al. (2009) The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50, 1827–1838.
34.Adams LA, Lymp JF, St Sauver J et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113–121.
35.Adams LA, Sanderson S, Lindor KD et al. (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42, 132–138.
36.Sanyal AJ, Banas C, Sargeant C et al. (2006) Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682–689.
37.El Serag HB & Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340, 745–750.
38.Paradis V, Zalinski S, Chelbi E et al. (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49, 851–859.
39.Promrat K, Kleiner DE, Niemeier HM et al. (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121–129.
40.Johnson NA, Sachinwalla T, Walton DW et al. (2009) Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50, 1105–1112.
41.Zivkovic AM, German JB & Sanyal AJ (2007) Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86, 285–300.
42.Musso G, Gambino R, De Michieli F et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909–916.
43.Cortez-Pinto H, Jesus L, Barros H et al. (2006) How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 25, 816–823.
44.Wang D, Wei Y & Pagliassotti MJ (2006) Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147, 943–951.
45.Musso G, Gambino R, Pacini G et al. (2009) Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 89, 558–567.
46.Ghafoorunissa, Ibrahim A, Rajkumar L et al. (2005) Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. J Nutr 135, 2634–2638.
47.Storlien LH, Kraegen EW, Chisholm DJ et al. (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237, 885–888.
48.Sekiya M, Yahagi N, Matsuzaka T et al. (2003) Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38, 1529–1539.
49.Capanni M, Calella F, Biagini MR et al. (2006) Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23, 1143–1151.
50.Tanaka N, Sano K, Horiuchi A et al. (2008) Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 42, 413–418.
51.Lee S, Gura KM & Puder M (2007) Omega-3 fatty acids and liver disease. Hepatology 45, 841–845.
52.Walkey CJ, Yu L, Agellon LB et al. (1998) Biochemical and evolutionary significance of phospholipid methylation. J Biol Chem 273, 27043–27046.
53.Yao ZM & Vance DE (1988) The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 263, 2998–3004.
54.Noga AA, Zhao Y & Vance DE (2002) An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 277, 42358–42365.
55.Fischer LM, da Costa KA, Kwock L et al. (2007) Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr 85, 1275–1285.
56.Zeisel SH & da Costa KA (2009) Choline: an essential nutrient for public health. Nutr Rev 67, 615–623.
57.Abdelmalek MF, Sanderson SO, Angulo P et al. (2009) Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50, 1818–1826.
58.Ouyang X, Cirillo P, Sautin Y et al. (2008) Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48, 993–999.
59.Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47, 711–717.
60.Stanhope KL & Havel PJ (2008) Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr 88, 1733S–1737S.
61.Teff KL, Elliott SS, Tschop M et al. (2004) Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 89, 2963–2972.
62.Ratziu V, Giral P, Jacqueminet S et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 135, 100–110.
63.Aithal GP, Thomas JA, Kaye PV et al. (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135, 1176–1184.
64.Harrison SA, Fecht W, Brunt EM et al. (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49, 80–86.
65.Sanyal AJ, Chalasani N, Kowdley KV et al. (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 362(18), 1675–1685.
66.Witek RP, Stone WC, Karaca FG et al. (2009) Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50, 1421–1430.
67.Anstee QM, Concas D, Kudo H et al. (2010) Impact of Pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. Journal of Hepatology. (In the Press).
68.Alberti KG & Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15, 539–553.
69.Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497.
70.Alberti KG, Zimmet P & Shaw J (2006) Metabolic syndrome – a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 469–480.
71.Alberti KG, Zimmet P & Shaw J (2005) The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062.
72.Bugianesi E, McCullough AJ & Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42, 987–1000.